4th Quarter - Report

TCH GROUP, LLC for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

H.R. 573, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs; authorized generic drug provisions. H.R. 1260, Patent Reform Act of 2009; reforms of the patent laws. H.R. 4899, Supplemental Appropriations Act, 2010: patent settlements. H.R. 5322, Patent and Trademark Office Funding Stabilization Act of 2010: Patent and Trademark Office Funding. S. 369, Preserve Access to Affordable Generics Act: patent settlements. S. 501, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions. S. 515, Patent Reform Act of 2009: reforms of the patent laws. S. 610, Patent Reform Act of 2009: reforms of the patent laws.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1260 (111th), S. 515 (111th), S. 369 (111th), S. 610 (111th), H.R. 5322 (111th), H.R. 573 (111th), S. 501 (111th), H.R. 4899 (111th)

Health Issues HCR

H.R. 1427, Promoting Innovations and Lifesaving Medicines Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, The Health Care and Education Reconciliation Act of 2010. S. 525, S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Issues pertaining to: prescription drug importation, comparative effectiveness, follow-on biologics, Medicare prescription drug coverage, Medicaid rebates. H.R. 444, 340B Program Improvement and Integrity Act: 340B program issues. H.R. 1298, Pharmaceutical Market Access and Drug Safety Act of 2009: importation. H.R. 2502, Comparative Effectiveness Research Act of 2009: comparative effectiveness. H.R. 2824, Doctor-Patient Relationship and Research Protection Act: comparative effectiveness. H.R. 5710, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2010: controlled substance monitoring. H.R. 5809, Safe Drug Disposal Act of 2010: disposal of controlled substances. S. 1203, Grow Research Opportunities with Taxcredits' Help Act: R&D tax credit provisions. S. 1213, Patient-Centered Outcomes Research Act of 2009: comparative effectiveness. S. 1679, Affordable Health Choices Act: 340B program issues, importation, and other health reform implementation issues. S. 3397, Secure and Responsible Drug Disposal Act of 2010: disposal of controlled substances General FDA advocacy.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 3397 (111th), S. 1232 (111th), H.R. 2502 (111th), H.R. 5710 (111th), H.R. 2824 (111th), H.R. 1298 (111th), S. 1213 (111th), H.R. 3590 (111th), H.R. 4872 (111th), S. 1203 (111th), H.R. 1427 (111th), H.R. 444 (111th), S. 525 (111th), H.R. 5809 (111th), S. 1679 (111th)

Medicare/Medicaid MMM

H.R. 3590, Patient Protection and Affordable Care Act: Part D coverage gap discounts, Part D rebates, Part D issues generally, Medicare payment issues, Medicaid rebate issues, transparency issues, comparative effectiveness, health reform fee and health reform issues generally. H.R. 4872, Healthcare & Education Reconciliation Act 2010. H.R. 4752, Medicare Prescription Drug Price Negotiation Act of 2010: Non-interference provisions. H.R. 4213, American Jobs & Closing Tax Loopholes Act of 2010: (AMP) issues. H.R. 4899, Supplemental Appropriations Act, 2010: AMP issues.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4872 (111th), H.R. 4899 (111th), H.R. 4213 (111th), H.R. 4752 (111th), H.R. 3590 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.